PAH

(redirected from Pulmonary Arterial Hypertension)
Also found in: Medical.
AcronymDefinition
PAHPolycyclic Aromatic Hydrocarbon (compound)
PAHPulmonary Arterial Hypertension
PAHPoly (Allylamine Hydrochloride)
PAHPolska Akcja Humanitarna
PAHPoly-Allylamine Hydrochloride
PAHPrint at Home (tickets)
PAHPhenylalanine Hydroxylase
PAHPfizer Animal Health (now Zoetis)
PAHPrint at Home
PAHPartners for Affordable Housing (various locations)
PAHPolynuclear Aromatic Hydrocarbon (compound)
PAHPolyaromatic Hydrocarbon
PAHPets At Home (UK pet supermarket chain)
PAHPrêt à l'Amélioration de l'Habitat (French: Housing Improvement Loan)
PAHPolychlorinated Aromatic Hydrocarbon
PAHP-Aminohippuric Acid
PAHPara-Aminohippuric Acid (used in renal function tests)
PAHProduction Approval Holder
PAHPaducah, KY, USA (Airport Code)
PAHPromoting Awareness in Healthcare
PAHPlatoon Area Hazard
PAHPosition Area Hazard
PAHPartners Against Hate
PAHPacific Andes Holdings (various locations)
PAHPayload Accommodations Handbook
PAHParents Are Home
PAHPrimary Account Holder
PAH4-Aminohippuric Acid (CAS Number 61-78-9)
PAHPretoria Akademiese Hospitaal (South Africa)
PAHPanzerabwehrhelikopter (German: Anti-Tank Helicopter)
PAHPersonnel Access Hatch
PAHPredictor At Home
PAHDepartment of Pathology at Pennsylvania Hospital
References in periodicals archive ?
NASDAQ: ARNA) has announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH), the company said.
Pharmaceutical company Cardiome Pharma Corp (NASDAQ:CRME) (TSX:COM) said on Monday that it has filed its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for TREVYENT (treprostinil injection) for the treatment of pulmonary arterial hypertension (PAH).
Methods: Eighty-six patients who developed COPD and pulmonary arterial hypertension and received treatment from August 2013 to October 2014 were selected and randomly divided into an observation group and a control group using random number table, 43 in each group.
Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.
Taking into account the poor prognosis for children with pulmonary arterial hypertension, new medications are needed, said Dr.
The study subjects were patients aged 12 and older who had idiopathic or heritable pulmonary arterial hypertension (PAH), or PAH related to connective tissue disease, repaired congenital systemic-to-pulmonary shunts, HIV infection, drug use, or toxin exposure, said Dr.
Among these conditions, idiopathic pulmonary arterial hypertension (TPAH previously known as primary pulmonary hypertension) is a rare disease with poor outcome in the absence of effective therapy.
GlobalData valued the global Pulmonary Arterial Hypertension (PAH) market to be worth $2,653m in 2009.
Key words: Pulmonary arterial hypertension, connective tissue diseases, systemic sclerosis
The finding has implications for future drug therapies that may extend the life of patients with pulmonary arterial hypertension and prevent the need for lung transplantation, currently the only cure for this debilitating disease.
The prevalence of pulmonary arterial hypertension (PAH) in a cohort of patients from the ItinerAir-HTAP registry, which is a 3-year, multicenter study of patients with systemic sclerosis, was found to be 7.
Full browser ?